These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 27609943)

  • 21. Relation between soluble ST2, growth differentiation factor-15, and high-sensitivity troponin I and incident atrial fibrillation.
    Rienstra M; Yin X; Larson MG; Fontes JD; Magnani JW; McManus DD; McCabe EL; Coglianese EE; Amponsah M; Ho JE; Januzzi JL; Wollert KC; Fradley MG; Vasan RS; Ellinor PT; Wang TJ; Benjamin EJ
    Am Heart J; 2014 Jan; 167(1):109-115.e2. PubMed ID: 24332149
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pro-atrial natriuretic peptide and prediction of atrial fibrillation and stroke: The Malmö Preventive Project.
    Berntsson J; Smith JG; Nilsson PM; Hedblad B; Melander O; Engström G
    Eur J Prev Cardiol; 2017 May; 24(8):788-795. PubMed ID: 28195503
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multicohort Metabolomics Analysis Discloses 9-Decenoylcarnitine to Be Associated With Incident Atrial Fibrillation.
    Lind L; Salihovic S; Sundström J; Broeckling CD; Magnusson PK; Prenni J; Fall T; Ärnlöv J
    J Am Heart Assoc; 2021 Jan; 10(2):e017579. PubMed ID: 33399003
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of a proximity extension assay proteomics chip to discover new biomarkers associated with albuminuria.
    Carlsson AC; Sundström J; Carrero JJ; Gustafsson S; Stenemo M; Larsson A; Lind L; Ärnlöv J
    Eur J Prev Cardiol; 2017 Mar; 24(4):340-348. PubMed ID: 27794105
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Natriuretic peptides in patients with atrial fibrillation and advanced chronic heart failure: determinants and prognostic value of (NT-)ANP and (NT-pro)BNP.
    Rienstra M; Van Gelder IC; Van den Berg MP; Boomsma F; Van Veldhuisen DJ
    Europace; 2006 Jul; 8(7):482-7. PubMed ID: 16798760
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma NT-proBNP levels and the risk of atrial fibrillation after major lung resection.
    Gurgo AM; Ciccone AM; D'Andrilli A; Ibrahim M; Musumeci B; Quarta G; Saponaro A; Rendina EA; Volpe M
    Minerva Cardioangiol; 2008 Dec; 56(6):581-5. PubMed ID: 19092733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. B-type natriuretic peptide level after sinus rhythm restoration in patients with persistent atrial fibrillation - clinical significance.
    Wozakowska-Kapłon B; Bartkowiak R; Grabowska U; Janiszewska G
    Kardiol Pol; 2010 Jul; 68(7):781-6. PubMed ID: 20648436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Growth Differentiation Factor 15 and the Subsequent Risk of Atrial Fibrillation: The Atherosclerosis Risk in Communities Study.
    Chen M; Ding N; Mok Y; Mathews L; Hoogeveen RC; Ballantyne CM; Chen LY; Coresh J; Matsushita K
    Clin Chem; 2022 Jul; 68(8):1084-1093. PubMed ID: 35762561
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protein Biomarkers and Risk of Atrial Fibrillation: The FHS.
    Staerk L; Preis SR; Lin H; Lubitz SA; Ellinor PT; Levy D; Benjamin EJ; Trinquart L
    Circ Arrhythm Electrophysiol; 2020 Feb; 13(2):e007607. PubMed ID: 31941368
    [TBL] [Abstract][Full Text] [Related]  

  • 30. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation).
    Hijazi Z; Wallentin L; Siegbahn A; Andersson U; Christersson C; Ezekowitz J; Gersh BJ; Hanna M; Hohnloser S; Horowitz J; Huber K; Hylek EM; Lopes RD; McMurray JJ; Granger CB
    J Am Coll Cardiol; 2013 Jun; 61(22):2274-84. PubMed ID: 23563134
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discordant atrial natriuretic peptide and brain natriuretic peptide levels in lone atrial fibrillation.
    Ellinor PT; Low AF; Patton KK; Shea MA; Macrae CA
    J Am Coll Cardiol; 2005 Jan; 45(1):82-6. PubMed ID: 15629379
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A proteomic analysis of atrial fibrillation in a prospective longitudinal cohort (AGES-Reykjavik study).
    Jonmundsson T; Steindorsdottir AE; Austin TR; Frick EA; Axelsson GT; Launer L; Psaty BM; Loureiro J; Orth AP; Aspelund T; Emilsson V; Floyd JS; Jennings L; Gudnason V; Gudmundsdottir V
    Europace; 2023 Nov; 25(11):. PubMed ID: 37967346
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association Between Vascular Cell Adhesion Molecule 1 and Atrial Fibrillation.
    Willeit K; Pechlaner R; Willeit P; Skroblin P; Paulweber B; Schernthaner C; Toell T; Egger G; Weger S; Oberhollenzer M; Kedenko L; Iglseder B; Bonora E; Schett G; Mayr M; Willeit J; Kiechl S
    JAMA Cardiol; 2017 May; 2(5):516-523. PubMed ID: 28355442
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of preoperative natriuretic peptides and echocardiographic parameters in predicting new-onset atrial fibrillation after coronary artery bypass grafting: a prospective comparative study.
    Gibson PH; Croal BL; Cuthbertson BH; Rae D; McNeilly JD; Gibson G; Jeffrey RR; Buchan KG; El-Shafei H; Hillis GS
    Am Heart J; 2009 Aug; 158(2):244-51. PubMed ID: 19619701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inflammatory proteomics profiling for prediction of incident atrial fibrillation.
    Börschel CS; Ortega-Alonso A; Havulinna AS; Jousilahti P; Salmi M; Jalkanen S; Veikko S; Niiranen T; Schnabel RB
    Heart; 2023 Jun; 109(13):1000-1006. PubMed ID: 36801832
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.
    Hijazi Z; Oldgren J; Andersson U; Connolly SJ; Eikelboom JW; Ezekowitz MD; Reilly PA; Yusuf S; Siegbahn A; Wallentin L
    Am Heart J; 2017 Aug; 190():94-103. PubMed ID: 28760218
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High pro-BNP levels predict the occurrence of atrial fibrillation after cryptogenic stroke.
    Rodríguez-Yáñez M; Arias-Rivas S; Santamaría-Cadavid M; Sobrino T; Castillo J; Blanco M
    Neurology; 2013 Jul; 81(5):444-7. PubMed ID: 23803318
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma Ceramides and Sphingomyelins in Relation to Atrial Fibrillation Risk: The Cardiovascular Health Study.
    Jensen PN; Fretts AM; Hoofnagle AN; Sitlani CM; McKnight B; King IB; Siscovick DS; Psaty BM; Heckbert SR; Mozaffarian D; Sotoodehnia N; Lemaitre RN
    J Am Heart Assoc; 2020 Feb; 9(4):e012853. PubMed ID: 32019406
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Direct comparison of mid-regional pro-atrial natriuretic peptide with N-terminal pro B-type natriuretic peptide in the diagnosis of patients with atrial fibrillation and dyspnoea.
    Eckstein J; Potocki M; Murray K; Breidthardt T; Ziller R; Mosimann T; Klima T; Hoeller R; Moehring B; Sou SM; Rubini Gimenez M; Morgenthaler NG; Mueller C
    Heart; 2012 Oct; 98(20):1518-22. PubMed ID: 22865868
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relation of atrial fibrillation burden and N-terminal pro-brain natriuretic peptide.
    Plitt DC; Chung EH; Mounsey JP; Schwartz JD; Pursell IW; Gehi AK
    Am J Cardiol; 2013 May; 111(9):1315-8. PubMed ID: 23415637
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.